Guidance On Harmonization Of Patient-Focused Drug Development Is Years Away
Executive Summary
The International Council for Harmonization has proposed topics for a global PFDD guideline and is expected to begin work on it in the next few years. When finalized, the US FDA will issue it as draft guidance.
You may also be interested in...
EU Project Findings To ‘Instil Confidence’ In Using Patient Preference Studies
The European Medicines Agency’s endorsement of a framework that explains how drug and medical device sponsors can use patient preference studies to answer their research questions could help increase confidence in the conduct and acceptability of such studies.
Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency
Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.